Piper Sandler Upgrades Teva Pharma (TEVA) to Overweight, 'The Times They Are A-Changin’'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
4 small and mid-cap biopharma stocks to own according to BofA
February 9, 2024 8:00 PM ESTBofA Global Research has published a new analysis of the US biopharmaceutical sector, highlighting their preferred small- and mid-cap (SMID) stock selections in this field.
From a broader perspective, BofA believes the fundamentals of the biopharma sector remain solid, evidenced by the productivity of research and development (R&D) and external validation through mergers and acquisitions (M&A) activity.
Thanks to favorable conditions within the industry, the outlook on the broader group has become more positive compared to previous years, analysts led by Jason M. Gerberry said.
Heading into 2024, we are... More
